JMP Securities Reiterates Market Perform on Incyte
Incyte's Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics
Incyte Closes 5% Higher Bolstered by Zynyz Data, Guggenheim Note
Incyte Insider Sold Shares Worth $526,948, According to a Recent SEC Filing
Incyte Announces Promising New Data on Oncology Candidate at ESMO
Express News | Incyte Shares Are Trading Higher After B of A Securities and Guggenheim Raised Their Respective Price Targets on the Stock
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $64 to $92
Express News | B of A Securities Maintains Neutral on Incyte, Raises Price Target to $68
TD Cowen Sticks to Its Buy Rating for Incyte (INCY)
Express News | Incyte : Guggenheim Raises Target Price to $92 From $86
Incyte's Promising Clinical Data Balanced With Regulatory Uncertainty: A 'Hold' Recommendation
Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal...
Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted
Incyte Zynyz Improves Progression-free Survival in Anal Cancer
Unusual Options Activity: F, INCY and Others Attract Market Bets, F V/OI Ratio Reaches 416.7
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $80